Viewing Company Concordia International Corp | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Concordia International Corp Stock Symbol: CXR-T

Notes:

Formerly Concordia Healthcare Corp

Last Price Recorded: $0.7200 on 2017-10-20

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-10-18 SELL Brian Madden

It has lost the overwhelming majority of its value.  It is burdened with leverage.  It is important to step back and take a cold, clinical view of it.  The market does not care what you paid for it.  The prospects going forward don’t look very favourable for it.  The subordinate debt went into default this week.  The stock is more of a lottery ticket.


Price:
$1.210
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
Unknown
2017-10-11 DON'T BUY Christine Poole

She wouldn’t be buying this now, even though the stock price has come down dramatically from what it was a few years ago. This has only been public for about 4-5 years, and they’ve been buying assets. There is a lot of pricing pressure on the drugs they bought and paid a lot for. Has a lot of debt on their balance sheet. Debt to Enterprise EBITDA is over 11X. There is a big question as to how they are going to repay the debt when it comes due. Based on what they have now, it doesn’t seem sufficient.


Price:
$1.490
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
No
2017-10-05 WAIT Fabrice Taylor

He loves turnaround stories with lots of debt. When you get them right, they really move. This one is not a turnaround yet. It has a lot of things that you look for, what it doesn’t have are signs of a turnaround. Wait until you see two quarters of deleveraging and improving margins. The stock will move from there. It still has bankruptcy risks.


Price:
$1.590
Subject:
CANADIAN SMALL & MIDCAPS
Bias:
UNKNOWN
Owned:
Unknown
2017-09-20 PAST TOP PICK Zachary Curry

(A Top Pick June 21/16. Down 95%.) He sold this before the end of last year.


Price:
$1.520
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on CANADIAN MARKET
Owned:
No
2017-09-12 DON'T BUY Christine Poole

Doesn’t think this is investable. Net debt to EBITDA is about 11X, which is very high. They have absolutely no visibility in terms of pricing in the UK, because the whole pricing regime is changing. She can’t see how they are going to pay the debt which comes due in 2021.


Price:
$1.620
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2017-06-23 COMMENT James Hodgins

He is pessimistic on this. They recently hired another set of advisors to advise them on capital structure. That usually doesn’t end well for equity holders. Just had so much debt. The big UK acquisition they made really went south on them in a hurry. Expects debt holders are either going to want a massive equity dilution or for some kind of bankruptcy and restructuring. The equity is probably close to worthless.


Price:
$1.710
Subject:
MARKET NEUTRAL INVESTING: SMALL/MID-CAP
Bias:
BEARISH
Owned:
Unknown
2017-05-09 COMMENT Lyle Stein

This as not an investable name. They borrowed money to make a UK acquisition and are having issues with that.


Price:
$2.850
Subject:
CANADIAN
Bias:
CAUTIOUS
Owned:
No
2017-04-11 PAST TOP PICK Ryan Modesto

(A Top Pick March 3/16. Down 95%.) About 9 months ago, he advised his members that it was time to move on from this name.


Price:
$1.860
Subject:
CANADIAN SMALL & MIDCAPS
Bias:
UNKNOWN
Owned:
No
2017-02-23 DON'T BUY Brooke Thackray

Technically it has fallen off the face of the earth.  You are making a gamble at this point.  He would not move into healthcare at this time of the year.


Price:
$3.070
Subject:
TECHNICAL ANALYSIS & SEASONAL INVESTING
Bias:
CAUTIOUS
Owned:
Unknown
2017-02-22 COMMENT Paul Macdonald

If looking to be exposed to all the positive attributes about global healthcare, this is not a company he would be focusing on.


Price:
$3.070
Subject:
HEALTHCARE
Bias:
BULLISH on HEALTH CARE
Owned:
Unknown
2017-02-01 DON'T BUY Brendan Caldwell

Concordia (CXR-T) or Valeant (VRX-T)? He wouldn’t pick either because whenever you have accounting irregularities, that never gets better, especially in Canada. This sector is under so much heat right now. The US president has really focused in on even legitimate drug companies and there is going to be a lot of scrutiny. doesn’t think either will survive.


Price:
$2.900
Subject:
CANADIAN VALUE
Bias:
OPTIMISTIC
Owned:
No
2017-01-05 WAIT Brian Acker, CA

It is dead money.  This has been a disaster.  You are going to see a lot of write-offs from this company.  You have to wait for the write-offs.  His model price is a little misnomer.  You could hold it if you own it.


Price:
$2.900
Subject:
NORTH AMERICAN - LARGE
Bias:
BULL
Owned:
Unknown
2016-12-23 SELL John Zechner

A lot of people took a bath this year. There were a few additional issues that came up. BREXIT hurt them more than expected. The acquisition of Amco was based primarily in Britain, and the currency translation really hurt. Also, they have generic competition for some of their US drugs. When you have a large debt outstanding, there is no room in your equity. Sold his holdings in the high teens. He doesn’t know if they will survive. Take a tax loss today, and then later on you can buy it back.


Price:
$2.910
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
2016-12-01 COMMENT Ross Healy

Very, very cheap. Sells at Price to Book at about 3. Of that book value, to all sense and purposes, it is all “goodwill”, which he might refer to as water in a portfolio. Analysts have been slow in pulling down their earnings forecasts.


Price:
$3.550
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Unknown
2016-11-30 COMMENT Lyle Stein

Not a company that is investable at the current price. They have a massive debt load. The UK is changing the rules with respect to generic drugs. They’ve had management changes. Incredibly speculative.


Price:
$3.550
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
No
Showing 1 to 15 of 200 entries
<< < 1 2 3 4 5 > >>

5 Comments

uptick

October 14th 2015 at 10:14am

I hope this company drops to zero for ethical reasons.

barney11

October 21st 2015 at 4:41pm

I do not invest in healthcare but seeing this zero comment (meaningless) and watching BNN interview the CEO of Concordia today I must comment. My concern is BNN is starting to act more like FOX TV for negative sensation than ever before. We know you are intelligent A, you do not have to prove yourself by subtly attacking the interviewee with 100% negativity. One positive question would make your approach more credible.

Martin Gutnik, LL.B.

September 17th 2016 at 9:30am

To the point raised by barney11 on October 21, 2015 - I must credit the BNN interview of the CEO and agree with BNN (and disagree with barney 11) that the only useful way to present information in a fair manner is to ask the hard questions and play devils advocate. You can be certain that executives form companies that are publicly traded will offer up the best spin on everything to entice buyers of their company stock. To be fair - they must be challenged. There are people out there investing their hard earned dollars and they deserve to know the downside risks. If anything - I find that the interviews are too soft on the executives. But made for television analysis must be kind or else there would be few guests to interview. By the way - look at the collapse of this particular stock and tell me now that you think the interview was too negative!!!!

Martin Gutnik, LL.B.

September 17th 2016 at 9:30am

To the point raised by barney11 on October 21, 2015 - I must credit the BNN interview of the CEO and agree with BNN (and disagree with barney 11) that the only useful way to present information in a fair manner is to ask the hard questions and play devils advocate. You can be certain that executives form companies that are publicly traded will offer up the best spin on everything to entice buyers of their company stock. To be fair - they must be challenged. There are people out there investing their hard earned dollars and they deserve to know the downside risks. If anything - I find that the interviews are too soft on the executives. But made for television analysis must be kind or else there would be few guests to interview. By the way - look at the collapse of this particular stock and tell me now that you think the interview was too negative!!!!

barney11

September 17th 2016 at 6:51pm

Martin, a year later you missed the point and obviously did not watch the interview. Would you have bothered to make your comment if CRX was up $100."A" has not repeated the same approach since, and I believe she is maturing in her assignment.


You must be logged in to comment.